Skip to main content
Log in

Frauen mit Epilepsie vor und während der Schwangerschaft

Therapeutisches Management

Women with epilepsy before and during pregnancy

Therapeutic management

  • Leitthema
  • Published:
Zeitschrift für Epileptologie Aims and scope Submit manuscript

Zusammenfassung

Epilepsie ist eine häufige Erkrankung. Epilepsiekranke Frauen mit Kinderwunsch haben einen erhöhten Beratungsbedarf bezüglich einer Schwangerschaft. Die meisten dieser Frauen bekommen gesunde Kinder. Dennoch ist die Fehlbildungsrate ihrer Kinder erhöht. Günstig ist eine so niedrig wie möglich dosierte Monotherapie, idealerweise mit Lamotrigin oder Levetiracetam. Nichtempfehlenswert ist Valproat. Polytherapien erhöhen das Risiko für Fehlbildungen. Während der Schwangerschaft sollte insbesondere unter Lamotrigin- und Oxcarbazepingabe der Serumspiegel engmaschig kontrolliert werden, da es häufig zu einem Abfall der Serumkonzentration und hierdurch zu Anfallsrezidiven kommt. Bereits vor der Empfängnis sollten Frauen, die Antiepileptika einnehmen, täglich 5 mg Folsäure einnehmen. Die Epilepsie ist kein Grund für einen Kaiserschnitt. Die Geburt sollte aber in einem Haus mit Neonatologie und Neurologie erfolgen. Stillen ist auch unter Antiepileptika zu empfehlen. Nach der Geburt sollte auf Überdosierungserscheinungen bei Mutter der geachtet werden, insbesondere wenn sie Lamotrigin, Oxcarbazepin oder Levetiracetam einnimmt.

Abstract

Epilepsy is a common disease. Women with epilepsy who want to become pregnant often have concerns regarding the baby’s health and need special counseling. Most of these women will have healthy children; nevertheless the malformation rate is elevated. Ideally, antiepileptic drugs should be taken in monotherapy and with the lowest possible dose. According to the current literature the drugs causing the lowest malformation rates are lamotrigine and levetiracetam. Valproate should be avoided. Valproate-associated malformation rates are dose-dependant but if unavoidable, doses lower than 1,000 mg daily should be given. Polytherapy is associated with higher malformation rates. During pregnancy serum levels of lamotrigine and oxcarbazepine should be closely monitored because serum concentrations fall during pregnancy often resulting in seizure recurrence. Even before conception women on antiepileptic drugs should take 5 mg folic acid daily. Epilepsy per se is not an indication for a caesarean section; however, women should give birth in a hospital with departments of neurology and neonatology. Breast feeding is recommended. The mother should be monitored for signs of an overdose especially when taking oxcarbazepine, lamotrigine or levetiracetam.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Adab N (2004) The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 75:1575–1583

    Article  PubMed  CAS  Google Scholar 

  2. Bauer J, Bös M, Rück J, Stoffel-Wagner B (2010) Folsäuresubstitution bei Frauen mit Epilepsie. Nervenarzt 82:459–461

    Article  Google Scholar 

  3. Gjerde IO, Strandjord RE, Ulstein M (1988) The course of epilepsy during pregnancy: a study of 78 cases. Acta Neurol Scand 78:198–205

    Article  PubMed  CAS  Google Scholar 

  4. Harden CL, Penell PB, Koppel BS et al (2009) Practice parameter update: management issues for women with epilepsy – focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: report of the quality standards subcommittee and therapeutics and technology subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 73:142–149

    Article  PubMed  CAS  Google Scholar 

  5. Harden CL, Meador KJ, Penell PB et al (2009) Practice parameter update: management issues for women with epilepsy – focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes. Report of the quality standards subcommittee and therapeutics and technology subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 73:133–141

    Article  PubMed  CAS  Google Scholar 

  6. Hunt S, Russell A, Smithson WH et al (2008) Topiramate in pregnancy - preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 71:272–276

    Article  PubMed  CAS  Google Scholar 

  7. Krämer G, Hösli I, Glanzmann R (2002) Levetiracetam accumulation in human breast milk. Epilepsia 43(suppl.):105

    Google Scholar 

  8. May TW, Pfafflin M, Coban I, Schmitz B (2009) Frauen mit Epilepsie: Befürchtungen, Wissen, Beratungsbedarf. Nervenarzt 80:174–183

    Article  PubMed  CAS  Google Scholar 

  9. Meador KJ, Baker GA, Browning N et al for the NEAD Study Group (2013) Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol 12:244–252

    Article  PubMed  CAS  Google Scholar 

  10. Mølgaard-Nielsen D, Hviid A (2011) Newer-generation Antiepileptic drugs and the risk of major birth defects. JAMA 305:1996–2002

    Article  PubMed  Google Scholar 

  11. Morrow J, Russell A, Guthrie E et al (2006) Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 77:193–198

    Article  PubMed  CAS  Google Scholar 

  12. Morrow JI, Hunt SJ, Russell AJ et al (2009) Folic acid use and major congenital malformations in offspring of women with epilepsy: a prospective study from the UK epilepsy and pregnancy register. J Neurol Neurosurg Psychiatry 80:506–511

    Article  PubMed  CAS  Google Scholar 

  13. Pennell PB (2003) Antiepileptic drug pharmacokinetics during pregnancy and lactation. Neurology 61:35–42

    Article  Google Scholar 

  14. Pennell PB, Peng L, Newport DJ et al (2008) Lamotrigine in pregnancy. Clearance, therapeutic drug monitoring, and seizure frequency. Neurology 70:2130–2136

    Article  PubMed  CAS  Google Scholar 

  15. Reimers A, Brodtkorb E (2012) Second-generation antiepileptic drugs and pregnancy: a guide for clinicians. Expert Rev Neuroth 12:707–717

    Article  CAS  Google Scholar 

  16. Sabers A (2012) Algorithm for lamotrigine dose adjustment before, during, and after pregnancy. Acta Neurol Scand 126:e1–e4

    Article  PubMed  CAS  Google Scholar 

  17. Schmitz B, Dennig D, Rating D et al (2010) Valproat in der Behandlung epilepsiekranker Frauen Eine Stellungnahme der Deutschen Gesellschaft für Epileptologie. Nervenarzt 81:747–752

    Article  PubMed  CAS  Google Scholar 

  18. Schneider U, Kunze A, Schleussner E, Hagemann G (2011) Epilepsie und Scwangerschaft. Gynäkologe 44:956–962

    Article  Google Scholar 

  19. Schulz B, Cossa N, Christofzik D et al (2012) German registry of antiepileptic drugs and pregnancy – interim report September 2012. http://www.eurap.de

  20. Senf P, Schmitz B (2009) Epilepsie: Unsicherheit vermeiden. AP Neurologie Psychiatrie 34–39

  21. Senf P, Schmitz B (2011) EURAP-Register-Antiepileptika in der Schwangerschaft Ein Projekt für mehr Sicherheit. Gynäkologe 44:963–968

    Article  CAS  Google Scholar 

  22. Shallcross R, Bromley B, Irwin B et al (2011) Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology 76:383–399

    Article  PubMed  CAS  Google Scholar 

  23. EURAP Study Group (2006) Seizure control and treatment in pregnancy – Observations from the EURAP Epilepsy Pregnancy Registry. Neurology 66:354–360

    Article  Google Scholar 

  24. EURAP Study Group (2009) Utilisation of antiepileptic drugs during pregnancy: comparative patterns in 38 countries based on data from the EURAP registry. 50:2305–2309

  25. Tomson T, Lindbom U, Ekquist B, Sundqvist A (1994) Epilepsy and pregnancy: a prospective study of seizure control in relation to free and total plasma concentrations of carbamazepine and phenytoin. Epilepsia 35:122–130

    Article  PubMed  CAS  Google Scholar 

  26. Tomson T, Luef G, Sabers A et al (2006) Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives. Neurology 67:1297–1299

    Article  PubMed  CAS  Google Scholar 

  27. Tomson T, Palm R, Källén K et al (2007) Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilepsia 48:1111–1116

    Article  PubMed  CAS  Google Scholar 

  28. Tomson T, Battino D, Bonizzoni E et al (2011) Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 10:609–617

    Article  PubMed  CAS  Google Scholar 

  29. Weil S, Luef G (2012) Familienplanung bei Epilepsiepatientinnen. Nervenarzt 83:195–200

    Article  PubMed  CAS  Google Scholar 

  30. Westin AA, Reimers A, Helde G et al (2008) Serum concentration/dose ratio of levetiracetam before, during and after pregnancy. Seizure 17:192–198

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Die korrespondierende Autorin gibt für sich und ihre Koautorin an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M. Bengner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bengner, M., Schmitz, B. Frauen mit Epilepsie vor und während der Schwangerschaft. Z. Epileptol. 26, 154–159 (2013). https://doi.org/10.1007/s10309-013-0306-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10309-013-0306-6

Schlüsselwörter

Keywords

Navigation